➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Dow
McKinsey
Merck
Medtronic
Moodys

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ARSENIC TRIOXIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for arsenic trioxide

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT00225992 Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS) Terminated Oncology Specialties, Alabama Phase 2 2004-02-01 In this phase II study besides evaluating for safety, the primary efficacy parameter is to evaluate the incidence of patients who have had a response to Trisenox by evidence of increased blood counts (red, white, or platelets) and/or by decrease or transfusion dependency. The secondary efficacy parameter is the assessment of the tolerability of the new dosing schedule. Arsenic trioxide will be administered intravenously over 1 to 2 hours with a loading dose of 0.30mg/kg for days 1-5 of the first week and then twice weekly for 27 weeks for a total of 28 weeks.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for arsenic trioxide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003395 Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer Completed National Cancer Institute (NCI) Phase 1 1998-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced hematologic cancer.
NCT00003395 Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer Completed Memorial Sloan Kettering Cancer Center Phase 1 1998-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced hematologic cancer.
NCT00003630 Arsenic Trioxide in Treating Patients With Advanced Solid Tumors Completed National Cancer Institute (NCI) Phase 1 1998-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced solid tumors.
NCT00003630 Arsenic Trioxide in Treating Patients With Advanced Solid Tumors Completed Memorial Sloan Kettering Cancer Center Phase 1 1998-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced solid tumors.
NCT00003885 Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma Unknown status Our Lady of Mercy Medical Center Phase 2 1997-11-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent or refractory acute leukemia, chronic myeloid leukemia, myelodysplasia, lymphoma, or myeloma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for arsenic trioxide

Condition Name

Condition Name for arsenic trioxide
Intervention Trials
Leukemia 31
Acute Promyelocytic Leukemia 12
Myelodysplastic Syndromes 11
Multiple Myeloma and Plasma Cell Neoplasm 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for arsenic trioxide
Intervention Trials
Leukemia 59
Leukemia, Promyelocytic, Acute 28
Leukemia, Myeloid 20
Neoplasms, Plasma Cell 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for arsenic trioxide

Trials by Country

Trials by Country for arsenic trioxide
Location Trials
United States 308
China 20
Spain 9
Canada 9
India 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for arsenic trioxide
Location Trials
New York 27
California 23
Texas 18
Illinois 17
Florida 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for arsenic trioxide

Clinical Trial Phase

Clinical Trial Phase for arsenic trioxide
Clinical Trial Phase Trials
Phase 4 4
Phase 3 10
Phase 2/Phase 3 3
[disabled in preview] 76
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for arsenic trioxide
Clinical Trial Phase Trials
Completed 53
Terminated 20
Recruiting 19
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for arsenic trioxide

Sponsor Name

Sponsor Name for arsenic trioxide
Sponsor Trials
National Cancer Institute (NCI) 50
Cephalon 12
Memorial Sloan Kettering Cancer Center 11
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for arsenic trioxide
Sponsor Trials
Other 133
NIH 52
Industry 36
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Harvard Business School
Colorcon
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.